Equities Analysts Offer Predictions for JSPR Q1 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research note issued to investors on Thursday, February 27th. William Blair analyst M. Phipps anticipates that the company will post earnings per share of ($1.14) for the quarter. The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.47) per share. William Blair also issued estimates for Jasper Therapeutics' Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.20) EPS, Q4 2026 earnings at ($1.22) EPS and FY2028 earnings at ($3.90) EPS.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.35).

A number of other analysts have also recently weighed in on JSPR. HC Wainwright cut their price target on Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. JMP Securities reissued a "market outperform" rating and set a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday, January 6th. Royal Bank of Canada lowered their price target on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a report on Thursday, January 9th. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an "outperform" rating and a $63.00 price objective on the stock. Finally, UBS Group initiated coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $38.00 price objective for the company. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $64.44.

Remove Ads

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock traded down $0.36 during trading on Monday, hitting $5.33. 156,527 shares of the stock were exchanged, compared to its average volume of 685,587. The firm's 50-day moving average price is $8.67 and its 200 day moving average price is $16.48. The stock has a market cap of $79.88 million, a price-to-earnings ratio of -1.13 and a beta of 2.11. Jasper Therapeutics has a 12-month low of $4.55 and a 12-month high of $31.01.

Institutional Trading of Jasper Therapeutics

A number of large investors have recently bought and sold shares of JSPR. Rhumbline Advisers increased its stake in Jasper Therapeutics by 12.6% in the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company's stock valued at $316,000 after purchasing an additional 1,652 shares during the period. BNP Paribas Financial Markets increased its position in Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after acquiring an additional 1,698 shares during the period. Barclays PLC raised its stake in Jasper Therapeutics by 13.6% during the 4th quarter. Barclays PLC now owns 18,334 shares of the company's stock valued at $392,000 after acquiring an additional 2,188 shares during the last quarter. Wellington Management Group LLP raised its stake in Jasper Therapeutics by 13.9% during the 4th quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock valued at $579,000 after acquiring an additional 3,310 shares during the last quarter. Finally, Fernwood Investment Management LLC lifted its position in Jasper Therapeutics by 6.9% during the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company's stock worth $995,000 after acquiring an additional 3,427 shares during the period. Institutional investors and hedge funds own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.